OPKO Health (OPK) Announces Presentation of RAYALDEE Data in CKD; Serum Level Considered 'Sufficient'
Tweet Send to a Friend
OPKO Health, Inc. (Nasdaq: OPK), announced that data on RAYALDEE (calcifediol) extended-release capsules as a treatment for secondary hyperparathyroidism (SHPT) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
